miRNA 320a as biomarker for inflammatory bowel disease
AssigneeWestfaelische Wilhelms-Universitaet Muenster
InventorsAlexander Schmidt, Christoph Cichon
Life of this patent
Estimating the term…
Abstract
The present invention relates to an in vitro method for diagnosing an acute or relapsing phase of inflammatory bowel disease as well as a method for treating the acute or relapsing phase of inflammatory bowel disease. In addition, the present invention relates to a medicament for use in the treatment of inflammatory bowel disease. Further comprised by the present invention is the use of a nucleic acid molecule of SEQ ID NO: 1 or 2 for monitoring the progression of said disease and in vitro diagnosis of an acute or relapsing phase of said disease. Also a device for the diagnosis of said disease and kits for performing the method of the present invention are envisaged by the present invention.
Claims16
An in vitro method for diagnosing an acute or relapsing phase of inflammatory bowel disease in a subject, the method comprising
- i) determining the level of a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:
- 1 or 2 in a test sample of stool, urine, blood, or saliva;
- ii) comparing the level of the nucleic acid molecule determined in the test sample with a control sample;
- wherein an elevation of said nucleic acid molecule in the test sample is indicative of an acute or relapsing phase of said inflammatory bowel disease;
- and
- iii) treating the subject diagnosed with the acute or relapsing phase of inflammatory bowel disease with a medicament.
A method for treating an acute or relapsing phase of inflammatory bowel disease in a subject comprising:
- (a) determining the level of the nucleotide sequence of SEQ ID NO:
- 1 or 2 in a test sample of stool, urine, blood, or saliva;
- (b) determining the level of S 1008A mRNA in said test sample;
- (c) comparing both levels to a control sample or control value;
- and
- (d) treating said subject with a medicament, provided that said test sample is characterized by an increase of said level of the nucleotide sequence of SEQ ID NO:
- 1 or 2 and by no alteration of said level of the S1008A mRNA in comparison to said control sample or control value.
Dependencies are inferred from the claim text.